Independent analysis of GLP-1 treatment costs, access, and transparency.
GLP-1 Primer Research independently tracks GLP-1 treatment prices, program fees, access pathways, and consumer disclosure practices across selected U.S. treatment programs. Our flagship product is the Cost & Access Index — a structured, source-backed analysis designed to help consumers understand what programs advertise, what they actually charge, and how clearly they disclose the terms that affect real out-of-pocket costs.
What we measure
- Advertised prices, continuing prices, and required fees
- Access models — insurance acceptance, cash-pay, prior-authorization support
- Dose-dependent pricing structures
- Disclosure of pharmacy, prescribing entity, membership, and cancellation terms
- Whether medication is FDA-approved or compounded
- Estimated first-year total cost based on required charges only
What we do not evaluate
- Which medication is medically best for any individual
- Which provider is clinically safest
- Whether a compounded prescription is legally appropriate
- Whether an individual qualifies for insurance coverage
- Medication safety, purity, or effectiveness
- Whether a provider is generally "good" or "bad"
We do not create clinical-quality scores, safety scores, legality scores, or "best provider" rankings.
Cost & Access Index
Methodology2026 GLP-1 Cost & Access Index — Q3 Edition
The first full edition of the Cost & Access Index is currently in development. It will not be published until at least 10 programs meet our completeness requirements, every current price has an observation date, every material claim has a source, and an admin approves publication. In the meantime, you can review the methodology and explore the pilot program profiles below.
Program Research Profiles
Program research profiles are being prepared. Each profile must pass completeness review — including source-backed pricing, disclosure observations, and editorial review — before publication.
Cost Case Studies
Case studies are in preparation. They will illustrate first-year cost scenarios for different access pathways.
Recent Market Changes
No verified market changes have been published yet. Changes are reviewed before publication.
Cost Calculator
Estimate your own treatment costs with our free tool.
Costs & Access Guides
Educational guides on insurance, cash-pay, and access pathways.
Corrections
Found an error? Submit a correction for review.
Research Disclaimer
GLP-1 Primer is an independent educational resource. We do not prescribe medication, provide medical advice, or determine insurance eligibility. Program inclusion in the Cost & Access Index is not an endorsement. We do not evaluate clinical quality, medication safety, product purity, regulatory compliance, or clinical appropriateness.
Prices and program terms may change at any time. Compounded medication is not FDA-approved and is not a generic version of a branded medication. Always consult a qualified healthcare professional before starting or changing any medication.
GLP-1 Primer may earn affiliate commissions from some linked programs. This does not influence research findings, program inclusion, or editorial conclusions. Read our full Editorial Policy.
Last updated: August 28, 2026
